ABSTRACT
BACKGROUND & AIMS: Several advanced therapies (biologic therapies and small molecules) have been approved for the treatment of moderate-to-severe ulcerative colitis. The registration trials for these agents typically excluded patients with isolated proctitis, leaving an evidence gap. We evaluated efficacy and safety of advanced therapies in patients with ulcerative proctitis (UP). METHODS: This multicenter retrospective cohort study included consecutive patients with active UP (Mayo endoscopy subscore of ≥2, rectal inflammation up to 15 cm) initiating advanced therapy, after failing conventional therapy. The primary end point was short-term steroid-free clinical remission (total Mayo score ≤2 with no individual subscore >1). In addition, drug persistence and relapse-free and colectomy-free survival were assessed. Both binary logistic and Cox regression analyses were performed. RESULTS: In total, 167 consecutive patients (52.0% female; median age 41.0 years; 82.0% bionaive) underwent 223 courses of therapy for UP (38 adalimumab, 14 golimumab, 54 infliximab, 9 ustekinumab, 99 vedolizumab, 9 tofacitinib). The primary end point was achieved with 36.3% of the treatment courses, and based on multivariate analysis, more commonly attained in bionaive patients (P = .001), patients treated with vedolizumab (P = .001), patients with moderate endoscopic disease activity (P = .002), and a body mass index <25 kg/m2 (P = .018). Drug persistence was significantly higher in patients treated with vedolizumab (P < .001) and patients with a shorter disease duration (P = .006). No new safety signals were observed. CONCLUSIONS: Advanced therapies are also efficacious and safe in patients with ulcerative colitis limited to the rectum. Therefore, the inclusion of patients with UP in future randomized-controlled trials should be considered.
Subject(s)
Colitis, Ulcerative , Humans , Female , Adult , Male , Colitis, Ulcerative/drug therapy , Retrospective Studies , Belgium , Adalimumab/therapeutic use , Biological Therapy , Treatment OutcomeABSTRACT
BACKGROUND: Self-expandable metal stents (SEMSs) have been suggested for the treatment of benign upper GI leaks and perforations. Nevertheless, uncomplicated removal remains difficult. Placement of a self-expandable plastic stent (SEPS) into an SEMS can facilitate retrieval. OBJECTIVES: This study reviews our experience with sequential SEMS/SEPS placement in patients with benign upper GI leaks or perforations. DESIGN: A retrospective review of the chart of each patient who underwent SEMS placement for benign upper GI leaks or perforations, including (1) fistula after bariatric surgery, (2) other postoperative fistulae, (3) Boerhaave syndrome, (4) iatrogenic perforations, and (5) other perforations. SETTING: Single, tertiary center. PATIENTS: Eighty-eight patients (37 male, average age 51.6 years, range 18-89 years). INTERVENTIONS: SEMS placement and removal, with or without SEPS placement. MAIN OUTCOME MEASUREMENTS: Feasibility of SEMS removal and successful treatment of lesions and short-term and long-term complications. RESULTS: A total of 153 SEMSs were placed in 88 patients; all placements were successful. Six patients died (not SEMS-related deaths) and 6 patients were lost to follow-up with SEMSs still in place. Seventy-three of the remaining 76 patients had successful SEMS removal (96.1%). The rate of successful SEMS removal per stent was 97.8% (132/135). Resolution of leaks and perforations was achieved in 59 patients (77.6%) with standard endoscopic treatment, and in 64 patients (84.2%) after prolonged, repeated endoscopic treatment. Spontaneous migration occurred in 11.1% of stents, and there were minor complications (dysphagia, hyperplasia, rupture of coating) in 20.9% and major complications (bleeding, perforation, tracheal compression) in 5.9%. LIMITATIONS: Retrospective design and highly selected patient population. CONCLUSIONS: Use of SEMSs for the treatment of benign upper GI leaks and perforations is feasible, relatively safe, and effective, and SEMSs can be easily removed 1 to 3 weeks after SEPS insertion. Leaks and perforations were closed in 77.6% of cases.
Subject(s)
Anastomotic Leak/surgery , Bariatric Surgery/adverse effects , Deglutition Disorders/surgery , Endoscopy, Gastrointestinal/methods , Esophageal Perforation/surgery , Esophagus/injuries , Mediastinal Diseases/surgery , Stents , Adolescent , Adult , Aged , Aged, 80 and over , Anastomotic Leak/diagnosis , Anastomotic Leak/etiology , Deglutition Disorders/diagnosis , Deglutition Disorders/etiology , Device Removal , Esophageal Perforation/complications , Esophageal Perforation/diagnosis , Esophagus/surgery , Female , Follow-Up Studies , Humans , Iatrogenic Disease , Male , Mediastinal Diseases/complications , Mediastinal Diseases/diagnosis , Middle Aged , Postoperative Complications , Prosthesis Design , Retrospective Studies , Rupture , Time Factors , Treatment Outcome , Young AdultABSTRACT
A young patient is described presenting with third-degree atrioventricular block, who had a flu-like syndrome a few weeks before admission. The diagnosis of Lyme disease was suspected by serologic antibody detection and confirmed by Western immunoblot assay. Pacing was necessary because an unstable escape rhythm persisted. After treatment, atrioventricular conduction recovered. Lyme disease, a tick borne disease, is discussed with emphasis on cardiac involvement: atrioventricular block is a frequent complication of early disseminated disease. If treated with adequate antibiotic therapy, the prognosis is good.
